|
2024
|
P/S
|
Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the trea... |
|
|
P/S
|
Pharmaceutical preparations for the treatment of cancer;
pharmaceutical preparations for the tre... |
|
2023
|
Invention
|
Methods for treating lower risk myelodysplastic syndrome. The present disclosure relates to the u... |
|
|
Invention
|
Ezh2 inhibition therapies for the treatment of brca1-associated protein (bap1) mutated cancers. P... |
|
|
Invention
|
Ezh2 inhibition therapies for the treatment of at-rich interactive domain-containing protein 1a (... |
|
|
Invention
|
Modulators of methyl modifying enzymes, compositions and uses thereof.
Provided are novel compou... |
|
|
P/S
|
Antibodies sold as a component ingredient of pharmaceuticals; antibodies for use in the manufactu... |
|
|
Invention
|
Anhydrous crystalline forms of 2-((4s)-6-(4-chlorophenyl)-1-methyl-4h-benzo[c]isoxazolo[4,5-e]aze... |
|
|
Invention
|
Modulators of trex1. Provided are compounds of Formula (I): and pharmaceutically acceptable salts... |
|
2022
|
Invention
|
Use of pelabresib for treating anemias.
The present disclosure relates to the use of pelabresib,... |
|
|
Invention
|
Use of pelabresib for treating anemias. The present disclosure relates to the use of pelabresib, ... |
|
|
Invention
|
Modulators of trex1.
Provided are compounds of Formula (I): and pharmaceutically acceptable salt... |
|
|
Invention
|
Methods of treating myeloproliferative disorders. The present disclosure relates to the use of 2-... |
|
|
Invention
|
Therapeutic compounds and uses thereof.
The present invention relates to a compound formula (I):... |
|
2021
|
Invention
|
Ezh2 inhibition therapies for the treatment of androgen receptor mutated prostate cancers.
Provi... |
|
|
Invention
|
Ezh2 inhibition therapies for the treatment of androgen receptor mutated prostate cancers. Provid... |
|
|
Invention
|
2-((4s)-6-(4-chlorophenyl)-1-methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide for treating... |
|
|
Invention
|
Substituted benzamides as modulators of trex1.
Provided are compounds of Formula (I): (I) and ph... |
|
|
Invention
|
Substituted benzamides as modulators of trex1. Provided are compounds of Formula (I): (I) and pha... |
|
|
Invention
|
Lsd1 inhibitors and medical uses thereof. Provided are novel compounds of Formula (I or Ia′): and... |
|
2020
|
Invention
|
Compounds for use in treating neurological disorders.
Provided are methods for treating neurolog... |
|
|
Invention
|
Compounds for use in treating neurological disorders. Provided are methods for treating neurologi... |
|
|
Invention
|
Alpha-amino amide compounds for use in treating neurological disorders. Provided are compounds of... |
|
|
Invention
|
Ezh2 inhibition in combination therapies for the treatment of cancers.
Provided herein are metho... |
|
|
Invention
|
Crystalline forms of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-n-((6-methyl-... |
|
|
Invention
|
Ezh2 inhibition therapies for the treatment of cancers. Provided herein are methods for treating ... |
|
|
Invention
|
P300/cbp hat inhibitors and methods for their use.
Provided are compounds of Formula (I): and ph... |
|
2019
|
Invention
|
Treating myeloproliferative disorders with cpi-0610 and a jak inhibitor. The present disclosure r... |
|
|
Invention
|
Modulators of methyl modifying enzymes, compositions and uses thereof. Provided are novel compoun... |
|
|
Invention
|
P300/cbp hat inhibitors. Provided are compounds of Formula (I): and pharmaceutically acceptable s... |
|
2018
|
Invention
|
Modulators of methyl modifying enzymes, compositions and uses thereof. Provided are compounds of ... |
|
|
P/S
|
Pharmaceutical preparations; pharmaceutical preparations for the treatment of cancer, inflammator... |
|
|
Invention
|
Ezh2 inhibitor-induced gene expression.
Provided herein are methods of treating subjects charact... |
|
|
P/S
|
Pharmaceutical preparations for the treatment of hematological diseases and disorders; pharmaceut... |
